At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).
Cancer treatment is steadily improving. The proof can be found in the number of patients with cancer living longer than ever before. Over the next decade, the number of people who have lived five or more years after their diagnosis is projected to increase approximately 30% to 16.3 million.
At the recent ASCO annual meeting, within hematologic malignancies, therapies for multiple myeloma stole the show, comme d’habitude.
In May, the American Society of Clinical Oncology released guidelines on the use of germline genetic testing panels in concert with tumor testing for cancer patients.1
A common perception of genetic screening is that only individuals at high risk of certain diseases will be identified.
Tumor heterogeneity is a well-recognized hurdle to successful cancer therapy, often leading to resistance and treatment failure.
In 2024, an estimated 6 million pet dogs will be diagnosed with cancer in the United States. As someone who has lost several family dogs to cancer, I know how heartbreaking this diagnosis will be for each of those dogs’ owners.
Over 18 million people are diagnosed with cancer in the United States and approximately 50% report clinical levels of depression and/or anxiety, pain, and/or fatigue.1-2
I recently attended a dinner party where guests lamented the use of generative AI in schools. They asked questions like, “Will kids stop learning and plug all their essay prompts into ChatGPT?”
For many women, a confirmation of pregnancy tends to evoke numerous emotions: excitement, shock, nervousness, joy, gratitude, and sometimes, even surprise. It is a moment dreamed, prayed, and planned for—but not for all.
